PL375306A1 - Upakowane cząstki wirusopodobne do zastosowania jako adiuwanty: sposoby wytwarzania i zastosowanie - Google Patents
Upakowane cząstki wirusopodobne do zastosowania jako adiuwanty: sposoby wytwarzania i zastosowanieInfo
- Publication number
- PL375306A1 PL375306A1 PL03375306A PL37530603A PL375306A1 PL 375306 A1 PL375306 A1 PL 375306A1 PL 03375306 A PL03375306 A PL 03375306A PL 37530603 A PL37530603 A PL 37530603A PL 375306 A1 PL375306 A1 PL 375306A1
- Authority
- PL
- Poland
- Prior art keywords
- vlps
- antigens
- packaged
- adjuvants
- particles
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 238000011260 co-administration Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38989802P | 2002-06-20 | 2002-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL375306A1 true PL375306A1 (pl) | 2005-11-28 |
Family
ID=30000481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03375306A PL375306A1 (pl) | 2002-06-20 | 2003-06-20 | Upakowane cząstki wirusopodobne do zastosowania jako adiuwanty: sposoby wytwarzania i zastosowanie |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20040005338A1 (pl) |
| EP (1) | EP1513552B1 (pl) |
| JP (1) | JP4598519B2 (pl) |
| CN (1) | CN1662253A (pl) |
| AT (1) | ATE489969T1 (pl) |
| AU (1) | AU2003242742B2 (pl) |
| BR (1) | BR0311995A (pl) |
| CA (1) | CA2488856A1 (pl) |
| DE (1) | DE60335186D1 (pl) |
| IL (1) | IL164812A0 (pl) |
| MX (1) | MXPA04011210A (pl) |
| NZ (1) | NZ537002A (pl) |
| PL (1) | PL375306A1 (pl) |
| RU (1) | RU2322257C2 (pl) |
| WO (1) | WO2004000351A1 (pl) |
| ZA (1) | ZA200408709B (pl) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094409B2 (en) * | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| EP1602720B1 (en) * | 2003-03-05 | 2010-11-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Process for producing heterologous protein in e. coli |
| EP1605972A2 (en) * | 2003-03-26 | 2005-12-21 | Cytos Biotechnology AG | Hiv-peptide-carrier-conjugates |
| US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
| US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
| ES2217967B1 (es) * | 2003-03-31 | 2006-01-01 | Consejo Sup. Investig. Cientificas | Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv. |
| EP1644034B1 (en) * | 2003-07-10 | 2011-01-12 | Cytos Biotechnology AG | Composition for enhancing an immune response comprising packaged virus-like particles |
| CA2544240A1 (en) * | 2003-07-22 | 2005-02-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| ES2307346B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
| ES2307345B1 (es) * | 2004-01-21 | 2009-11-13 | Consejo Sup. Investig. Cientificas | Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones. |
| JP3976742B2 (ja) * | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
| WO2006033679A2 (en) * | 2004-05-25 | 2006-03-30 | Chimeracore, Inc. | Self-assembling nanoparticle drug delivery system |
| CA2580208A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| WO2006037787A2 (en) * | 2004-10-05 | 2006-04-13 | Cytos Biotechnology Ag | Vlp-antigen conjugates and their uses as vaccines |
| ES2310062B1 (es) * | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| CN100418583C (zh) * | 2006-02-21 | 2008-09-17 | 朱鸿飞 | 预防和治疗乳腺炎的药物组合物 |
| CA2648581A1 (en) * | 2006-04-07 | 2008-09-12 | Chimeros, Inc. | Compositions and methods for treating b- cell malignancies |
| MX2008015529A (es) | 2006-06-12 | 2009-01-13 | Cytos Biotechnology Ag | Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn. |
| AU2013204383B2 (en) * | 2006-06-12 | 2016-09-22 | Kuros Us Llc | Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages |
| WO2008094200A2 (en) * | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| US9439959B2 (en) | 2006-07-27 | 2016-09-13 | Takeda Vaccines, Inc. | Chimeric influenza virus-like particles |
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| CA2671873C (en) * | 2006-12-12 | 2018-10-09 | Brian Stephen Sproat | Oligonucleotides containing high concentrations of guanine monomers |
| CA2683063A1 (en) * | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
| US8986597B2 (en) * | 2007-10-31 | 2015-03-24 | Corning Incorporated | Low creep refractory ceramic and method of making |
| WO2009060440A1 (en) * | 2007-11-05 | 2009-05-14 | Mor Research Applications Ltd. | Anti-measles cancer immunotherapy |
| NO339169B1 (no) * | 2008-04-24 | 2016-11-14 | Chemoforma Ltd | Funksjonelt fiskefôr omfattende peptidoglykan og nukleotider |
| AU2009279456B2 (en) * | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| EP3427755B1 (en) | 2009-04-13 | 2020-10-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Hpv particles and uses thereof |
| WO2010120874A2 (en) | 2009-04-14 | 2010-10-21 | Chimeros, Inc. | Chimeric therapeutics, compositions, and methods for using same |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| WO2011056899A2 (en) | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| RU2440141C1 (ru) * | 2010-05-31 | 2012-01-20 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Федеральный Университет" (Двфу) | Способ регуляции иммуногенности антигена |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| EA025417B1 (ru) * | 2010-11-22 | 2016-12-30 | Борис Славинович ФАРБЕР | Вакцины с повышенной иммуногенностью и способы их получения |
| KR101376675B1 (ko) * | 2011-04-19 | 2014-03-20 | 광주과학기술원 | 이미징 및 운반 이중기능 나노입자－기반 백신 전달체 |
| TWI454478B (zh) * | 2011-05-13 | 2014-10-01 | Academia Sinica | 類鐸受體-２ 增效劑及其用於刺激免疫反應之用途 |
| CA2841356C (en) | 2011-07-11 | 2022-03-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| CA2847888A1 (en) | 2011-09-09 | 2013-03-14 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| CN102512671A (zh) * | 2011-12-16 | 2012-06-27 | 厦门大学 | 抗o型口蹄疫的类病毒颗粒疫苗及其制备方法 |
| WO2013119877A1 (en) | 2012-02-07 | 2013-08-15 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| CN103421117B (zh) * | 2012-05-16 | 2016-08-03 | 李岱宗 | 一种免疫增强型病毒样颗粒、其表达载体及其制备与应用 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
| WO2015024992A2 (en) * | 2013-08-22 | 2015-02-26 | Cytos Biotechnology Ag | Treatment of asthma |
| MX385842B (es) | 2013-09-18 | 2025-03-18 | Aura Biosciences Inc | Conjugados de partículas de tipo virus y uso de las mismas. |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| US20150355147A1 (en) * | 2014-06-06 | 2015-12-10 | Biogénesis Bagó Uruguay S.A. | High throughput quantification and characterization of foot and mouth disease virus and products thereof |
| BR112017006679A2 (pt) | 2014-10-02 | 2017-12-26 | Protiva Biotherapeutics Inc | moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d |
| US10251970B1 (en) | 2014-12-30 | 2019-04-09 | Zee Company | Air sanitation apparatus for food processing tanks having air agitation piping and methods thereof |
| WO2017075440A1 (en) | 2015-10-30 | 2017-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Targeted cancer therapy |
| WO2017157437A1 (en) * | 2016-03-16 | 2017-09-21 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer |
| EP3295956A1 (en) | 2016-09-20 | 2018-03-21 | Biomay Ag | Polypeptide construct comprising fragments of allergens |
| TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類ｂ肝病毒顆粒作為佐劑的疫苗組成物 |
| IL269986B2 (en) | 2017-04-12 | 2024-06-01 | Aura Biosciences Inc | Targeted combination therapy |
| US12246031B2 (en) | 2018-02-13 | 2025-03-11 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| KR102890791B1 (ko) | 2018-04-09 | 2025-11-24 | 체크메이트 파마슈티칼스, 인크. | 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장 |
| WO2020029968A1 (zh) * | 2018-08-07 | 2020-02-13 | 中国科学院生物物理研究所 | 活化cd4+t细胞的方法 |
| CN110257922A (zh) * | 2019-07-19 | 2019-09-20 | 苏州盛天力离心机制造有限公司 | 羽毛洗涤脱水一体机 |
| JP2022543046A (ja) * | 2019-07-30 | 2022-10-07 | バーンダリ・インコーポレイテッド | ウイルス様粒子ワクチン |
| JP7072604B2 (ja) * | 2020-06-23 | 2022-05-20 | アンスティテュ・クリー | 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用 |
| WO2022051401A1 (en) * | 2020-09-02 | 2022-03-10 | The Regents Of The University Of California | Covid assay controls |
| CN114632148B (zh) * | 2020-12-15 | 2024-08-09 | 榕森生物科技(北京)有限公司 | 病原样抗原疫苗及其制备方法 |
| CN115927400A (zh) * | 2022-08-11 | 2023-04-07 | 中国动物卫生与流行病学中心 | 一种含口蹄疫病毒rna片段的假病毒颗粒及其制备方法和应用 |
| WO2025248564A1 (en) * | 2024-05-30 | 2025-12-04 | Protextent Biosolutions Private Limited | A novel virus-like particle platform based on intein-mediated bioconjugation with target antigen and encapsulated with immunomodulatory factors |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5374426A (en) * | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
| US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
| US4918166A (en) * | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP1690934A3 (en) * | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5334394A (en) * | 1990-06-22 | 1994-08-02 | The Regents Of The University Of California | Human immunodeficiency virus decoy |
| SE9003978D0 (sv) * | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| GB9114003D0 (en) * | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
| FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| US6004763A (en) * | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
| EP0678034B1 (en) * | 1993-01-11 | 1999-05-26 | Dana Farber Cancer Institute | Inducing cytotoxic t lymphocyte responses |
| WO1994017813A1 (en) * | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
| US6015686A (en) * | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| AU1218295A (en) * | 1993-12-09 | 1995-06-27 | Heinrich Exner | Adjuvant for antigens, process for producing the same and its use |
| US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| ATE509102T1 (de) * | 1994-07-15 | 2011-05-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US5935821A (en) * | 1995-01-17 | 1999-08-10 | Board Of Trustees Of The University Of Kentucky | Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5770380A (en) * | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| EP0980257A1 (en) * | 1997-05-01 | 2000-02-23 | Chiron Corporation | Use of virus-like particles as adjuvants |
| AU7690898A (en) * | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
| CN1313481C (zh) * | 1997-06-23 | 2007-05-02 | 路德维格癌症研究所 | 结合hla分子的分离的九肽和十肽及其应用 |
| US6054312A (en) * | 1997-08-29 | 2000-04-25 | Selective Genetics, Inc. | Receptor-mediated gene delivery using bacteriophage vectors |
| WO1999040934A1 (en) * | 1998-02-12 | 1999-08-19 | Immune Complex, Corporation | Strategically modified hepatitis b core proteins and their derivatives |
| ATE305507T1 (de) * | 1998-05-14 | 2005-10-15 | Coley Pharm Gmbh | Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide |
| US7049302B1 (en) * | 1998-08-10 | 2006-05-23 | Antigenics Inc. | Compositions of CPG and saponin adjuvants and uses thereof |
| US5962636A (en) * | 1998-08-12 | 1999-10-05 | Amgen Canada Inc. | Peptides capable of modulating inflammatory heart disease |
| NZ512456A (en) * | 1998-11-30 | 2003-10-31 | Cytos Biotechnology Ag | Ordered molecular presentation of antigens |
| US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
| SK287400B6 (sk) * | 1999-09-25 | 2010-08-09 | University Of Iowa Research Foundation | Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| AU781812B2 (en) * | 2000-01-13 | 2005-06-16 | Antigenics, Inc. | Innate immunity-stimulating compositions of CPG and saponin and methods thereof |
| EP1311288A1 (en) * | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| AT409085B (de) * | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| CA2407897A1 (en) * | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| MXPA03002640A (es) * | 2000-09-28 | 2003-06-19 | Chiron Corp | Microparticulas para la distribucion de acidos nucleicos heterologos. |
| JP2004511527A (ja) * | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
| AU2002339224B2 (en) * | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| EP2351770A1 (en) * | 2002-07-17 | 2011-08-03 | Cytos Biotechnology AG | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| NZ537003A (en) * | 2002-07-18 | 2008-03-28 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| MXPA04011247A (es) * | 2002-07-19 | 2005-02-17 | Cytos Biotechnology Ag | Conjugados portadores de grelina. |
| EP1605972A2 (en) * | 2003-03-26 | 2005-12-21 | Cytos Biotechnology AG | Hiv-peptide-carrier-conjugates |
-
2003
- 2003-06-20 CA CA002488856A patent/CA2488856A1/en not_active Abandoned
- 2003-06-20 RU RU2005101206/13A patent/RU2322257C2/ru not_active IP Right Cessation
- 2003-06-20 AU AU2003242742A patent/AU2003242742B2/en not_active Ceased
- 2003-06-20 EP EP03760672A patent/EP1513552B1/en not_active Expired - Lifetime
- 2003-06-20 DE DE60335186T patent/DE60335186D1/de not_active Expired - Lifetime
- 2003-06-20 MX MXPA04011210A patent/MXPA04011210A/es active IP Right Grant
- 2003-06-20 CN CN038142228A patent/CN1662253A/zh active Pending
- 2003-06-20 AT AT03760672T patent/ATE489969T1/de not_active IP Right Cessation
- 2003-06-20 US US10/465,811 patent/US20040005338A1/en not_active Abandoned
- 2003-06-20 JP JP2004514823A patent/JP4598519B2/ja not_active Expired - Fee Related
- 2003-06-20 BR BR0311995-5A patent/BR0311995A/pt not_active IP Right Cessation
- 2003-06-20 WO PCT/EP2003/006541 patent/WO2004000351A1/en not_active Ceased
- 2003-06-20 PL PL03375306A patent/PL375306A1/pl not_active Application Discontinuation
- 2003-06-20 NZ NZ537002A patent/NZ537002A/en not_active IP Right Cessation
-
2004
- 2004-06-20 IL IL16481204A patent/IL164812A0/xx unknown
- 2004-10-27 ZA ZA200408709A patent/ZA200408709B/en unknown
-
2010
- 2010-05-28 US US12/790,708 patent/US20110070267A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2322257C2 (ru) | 2008-04-20 |
| JP2006502979A (ja) | 2006-01-26 |
| MXPA04011210A (es) | 2005-02-14 |
| CN1662253A (zh) | 2005-08-31 |
| EP1513552B1 (en) | 2010-12-01 |
| BR0311995A (pt) | 2005-04-05 |
| HK1074578A1 (en) | 2005-11-18 |
| CA2488856A1 (en) | 2003-12-31 |
| WO2004000351A8 (en) | 2005-02-03 |
| RU2005101206A (ru) | 2005-06-27 |
| IL164812A0 (en) | 2005-12-18 |
| DE60335186D1 (de) | 2011-01-13 |
| JP4598519B2 (ja) | 2010-12-15 |
| AU2003242742A1 (en) | 2004-01-06 |
| AU2003242742B2 (en) | 2009-04-30 |
| US20040005338A1 (en) | 2004-01-08 |
| NZ537002A (en) | 2006-06-30 |
| ATE489969T1 (de) | 2010-12-15 |
| WO2004000351A1 (en) | 2003-12-31 |
| EP1513552A1 (en) | 2005-03-16 |
| ZA200408709B (en) | 2005-11-18 |
| US20110070267A1 (en) | 2011-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL164812A0 (en) | Packaged virus-like particles for use as adjuvants: method of preparation and use | |
| WO2003024481A3 (en) | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use | |
| WO2004084939A8 (en) | Hiv-peptide-carrier-conjugates | |
| Skrastina et al. | Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles | |
| IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
| DE602004031017D1 (de) | Zusammensetzung verpackte virusartige teilchen umfassend zur verstärkung einer immunantwort | |
| WO2002034205A3 (en) | Using heat shock proteins to increase immune response | |
| WO2001082963A3 (en) | Method of identifying and producing antigen peptides and use thereof as vaccines | |
| NO20062674L (no) | Optimalisert uttrykking av HPV58-L1 i gjaer | |
| WO2004084936A3 (en) | Modified free-living microbes, vaccine compositions and methods of use thereof | |
| WO2005009463A3 (en) | Antigen-presenting cell vaccines and methods of use thereof | |
| WO2004058157A3 (en) | Yeast-based vaccines as immunotherapy | |
| Mohammed et al. | Cancer vaccines: past, present, and future | |
| WO2005007673A3 (en) | Immunogenic peptides | |
| JP2023106591A (ja) | 既存の微生物免疫を利用した癌処置 | |
| JP2011519869A5 (pl) | ||
| AU2003246373A1 (en) | Recombinant measles viruses expressing epitopes pf antigens of rna viruses and use of the recombinant viruses for the preparation of vaccine compositions | |
| WO2009080715A3 (en) | Vaccines for malaria | |
| WO2003090687A3 (en) | Using heat shock proteins to increase immune response | |
| WO2008082719A3 (en) | Combined human papillomavirus vlp/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors | |
| WO2005012538A3 (en) | Accelerated vaccination | |
| NZ516725A (en) | Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus | |
| Hayek et al. | Vaccine adjuvants in the immunocompromised host: science, safety, and efficacy | |
| Zhu et al. | A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses | |
| EP1593738A4 (en) | VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |